Top News

US senator, Bob Menendez charged with taking bribes to help business cronies, Egyptian government

US senator, Bob Menendez charged with taking bribes to help business cronies, Egyptian government

Indonesian woman jailed for two years over ‘blasphemous’ Tiktok

Indonesian woman jailed for two years over ‘blasphemous’ Tiktok

chef-Pakistani

Pakistani Chef Triumphs in International Culinary Contest in Saudi Arabia

Load More
JKreativ WordPress theme

Popular News

  • Elon Musk says everyone on Twitter (X) will soon have to ‘PAY’

    Elon Musk says everyone on Twitter (X) will soon have to ‘PAY’

    720 shares
    Share 288 Tweet 180
  • Specifications, features and price of Apple iPhone 15 in Dubai

    712 shares
    Share 285 Tweet 178
  • UAE recognizes Gilgit-Baltistan, Kashmir as India’s territories at G20

    720 shares
    Share 288 Tweet 180
  • SC verdict reopens NAB cases against Former president, prime ministers

    702 shares
    Share 281 Tweet 176
  • Dunya Group terminates senior journalists

    603 shares
    Share 241 Tweet 151

Latest News

  • PTA tax on iPhone 15 series variants
  • Good News! Decline in Petroleum Prices Expected from October 1
  • Pakistan cancels pre-World Cup Dubai trip over Indian Visa delays
  • Saudi Arabia National Day: 37 million items at discounted prices, 4-day ‘sale season’
  • India’s space agency unable to communicate with Chandrayaan-3 Moon lander
Pakistan Rupee Exchange Rate
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Saturday, September 23, 2023
  • Login
Media Bites
  • Home
  • TOP NEWS
  • NEW JOININGS
  • BUSINESS
  • TECHNOLOGY
  • ENTERTAINMENT
  • WORLD
  • MEDIA
  • PAKISTAN
No Result
View All Result
Media Bites
Home BREAKING

Possible new treatment for people with deadly brain tumor

1.4k
VIEWS
Share on FacebookShare on TwitterShare on Whatsapp

Scientists co-leading an international study, including researchers from UCLA, have demonstrated that a new targeted therapy drug called vorasidenib can prolong the duration of treatment without cancer progression in individuals with a specific subtype of glioma. This finding suggests a potential new treatment option for patients with this slow-growing but lethal brain tumor.

The study focused on recurrent grade 2 glioma with IDH1 and IDH2 mutations, which primarily affects younger individuals, often in their 30s. The standard treatment, a combination of radiation and chemotherapy, can result in neurological deficits that hinder patients’ ability to learn, remember, concentrate, and make decisions—particularly challenging for those with young families or in early stages of their careers.

Vorasidenib, a dual inhibitor of mutant IDH1/2, was found to more than double the progression-free survival in patients with this glioma subtype. Compared to those who received a placebo, individuals treated with vorasidenib experienced almost 17 additional months without cancer progression, delaying the need for chemotherapy and radiation.

The research results were published in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Dr. Timothy Cloughesy, a professor of neuro-oncology at UCLA and co-senior author of the study, emphasized the significance of having a treatment that allows for longer intervals between chemotherapy and radiation sessions, thereby mitigating the delayed effects of radiation. He stated that this could have a major impact on patients in this particular population.Vorasidenib acts as a brain-penetrant inhibitor, effectively crossing the blood-brain barrier, which has been a significant challenge in developing targeted therapies for brain tumors.

The drug’s classification as a targeted therapy means it selectively attacks cancer cells with the mutated target, minimizing damage to healthy cells.The study involved 331 participants aged 12 and older diagnosed with recurrent grade 2 glioma with IDH1 and IDH2 mutations, who had undergone brain tumor surgery. Of these, 168 received vorasidenib and 163 received placebos.

Among those treated with vorasidenib, the disease did not progress for an average of 27.7 months, significantly longer than the 11.1 months for the placebo group. Moreover, 85.6% of patients in the vorasidenib group went for 18 months without requiring further treatment, while 83.4% went for 24 months.The disease progressed in only 28% of individuals receiving vorasidenib compared to 54% in the placebo group. As of September 2022, 72% of patients in the vorasidenib group were still on the drug without disease progression, which was 30 months after the study began.

For patients in the placebo group whose cancer progressed during the study, doctors allowed a switch to vorasidenib. The drug exhibited limited adverse side effects. Dr. Cloughesy described this targeted treatment as the first to demonstrate unequivocal efficacy in this patient population, setting a precedent for this disease.The study was sponsored by Servier Pharmaceuticals, the manufacturer of vorasidenib. However, the drug has not yet been approved by the FDA for clinical use.

Key participants in the research included Benjamin Ellingson, director of the UCLA Brain Tumor Imaging Laboratory,and Dr. Ingo Mellinghoff of Memorial Sloan-Kettering Cancer Center, the study’s first author. Dr. Patrick Wen of the Dana-Farber Cancer Institute also served as a co-senior author.

Share199Tweet124Send
media bites

media bites

Related Posts

Justice-Qazi-Faez-Isa

Justice Qazi Faez Isa assumes charge as 29th CJP as what will top to-do list?

Justice Qazi Faez Isa takes on the role of the 29th Chief Justice of the Supreme Court of Pakistan, he...

Bol-Network

AsiaPak Investments takes control of Bol Network

Bol Network, a prominent media company, revealed on Monday that it had been acquired by AsiaPak Investments, a private equity...

Shahid Khaqan Abbasi calls outgoing assembly ‘the worst’

Shahid Khaqan Abbasi calls outgoing assembly ‘the worst’

Former PM Shahid Khaqan Abbasi criticized the outgoing National Assembly, labeling it the 'worst' for passing almost 53 bills in...

President-national-assembly

President Alvi dissolves the National Assembly

President Arif Alvi formally signed the summary for the dissolution of the National Assembly (NA). “The president dissolved the National...

Latest News

  • PTA tax on iPhone 15 series variants
  • Good News! Decline in Petroleum Prices Expected from October 1
  • Pakistan cancels pre-World Cup Dubai trip over Indian Visa delays
  • Saudi Arabia National Day: 37 million items at discounted prices, 4-day ‘sale season’
  • India’s space agency unable to communicate with Chandrayaan-3 Moon lander
Pakistan Rupee Exchange Rate
Media Bites

Copyright © 2013 MediaBites.

Navigate Site

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Home
  • TOP NEWS
  • NEW JOININGS
  • BUSINESS
  • TECHNOLOGY
  • ENTERTAINMENT
  • WORLD
  • MEDIA
  • PAKISTAN

Copyright © 2013 MediaBites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In